Cluster subcutaneous allergen specific immunotherapy for the treatment of allergic rhinitis: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Feng, Shaoyan ^a   Xu, Ying ^b   Ma, Renqiang ^a   Sun, Yueqi ^a   Luo, Xi ^a   Li, Huabin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CAT HAIR AND DANDER EXTRACTION; DACTYLIS GLOMERATA ALLERGEN; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; PARIETARIA JUDAICA EXTRACT; PLACEBO; SALSOLA KALI ALLERGEN; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ARTICLE; DACTYLIS GLOMERATA; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; PARIETARIA; PARIETARIA JUDAICA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALSOLA; SALSOLA KALI; SUBCUTANEOUS IMMUNOTHERAPY; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; ADULT; DESENSITIZATION; IMMUNOLOGY; PUBLISHING; RHINITIS, ALLERGIC; RISK FACTOR; SUBCUTANEOUS TISSUE;

ADULT; DESENSITIZATION, IMMUNOLOGIC; HUMANS; PLACEBOS; PUBLICATION BIAS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC; RISK FACTORS; SUBCUTANEOUS TISSUE;

EID: 84900334810     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086529     Document Type: Article

References (39)

1. Greiner AN, Hellings PW, Rotiroti G, Scadding GK (2011) Allergic rhinitis. Lancet 378: 2112-2122.
2. Akdis CA (2012) Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med 18: 736-749.
3. Stokes JR, Casale TB (2011) Allergic rhinitis and asthma: celebrating 100 years of immunotherapy. Curr Opin Immunol 23: 808-813.
4. Bousquet J, Lockey R, Malling HJ (1998) Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102: 558-562.
5. More DR, Hagan LL (2002) Factors affecting compliance with allergen immunotherapy at a military medical center. Ann Allergy Asthma Immunol 88: 391-394. (Pubitemid 34408565)
6. Cox L, Compalati E, Kundig T, Larche M (2013) New directions in immunotherapy. Curr Allergy Asthma Rep 13: 178-195.
7. Fernández-Távora L, Justicia JL, Moreno C, Tabar AI, Vidal C (2011) Safety evaluation of rapid build-up schedules with IR-standardized allergen extracts for subcutaneous immunotherapy of allergic respiratory diseases. Expert Opin Drug Saf 10: 947-955.
8. Linda Cox (2006) Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol 97: 126-137.
9. Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0. The Cochrane Collaboration. Available: www.cochrane-handbook.org. Accessed 10 May 2013.
10. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558. (Pubitemid 34746062)
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. (Pubitemid 37088507)
12. Song F, Gilbody S (1998) Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis. BMJ 316: 471.
13. Hansen I, Hörmann K, Stuck BA, Schneider-Gêne S, Mösges R, et al. (2003) Cluster-immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal). Laryngorhinootologie 82: 558-563. (Pubitemid 37055560)
14. Guardia P, Moreno C, Justicia JL, Conde J, Cimarra M, et al. (2004) Tolerance and short-term effect of a cluster schedule with pollen-extracts quantified in mass-units. Allergol Immunopathol (Madr) 32: 271-277. (Pubitemid 39586037)
15. Pfaar O, Mösges R, Hörmann K, Klimek L (2010) Safety aspects of Cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhino-conjunctivitis. Eur Arch Otorhinolaryngol 267: 245-250.
16. Hernández N, Ibero M, Ridao M, Artigas R, Viñas M, et al. (2011) Safety of specific immunotherapy using a depigmented and polymerised extract of Dermatophagoides pteronyssinus in children under five years of age. Allergol Immunopathol (Madr) 39: 267-270.
17. Pichler CE, Helbling A, Pichler WJ (2001) Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 56: 301-306. (Pubitemid 32222609)
18. Serrano P, Algorta J, Martínez A, González-Quevedo T, Velázquez E, et al. (2004) Prospective safety study of immunotherapy administered in a cluster schedule. J Investig Allergol Clin Immunol 14: 312-319. (Pubitemid 40378865)
19. Rossi RE, Monasterolo G (2004) Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)-specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients. Int Arch Allergy Immunol 135: 44-53. (Pubitemid 39279431)
20. Tabar AI, Fernández-Távora L, Alonso R, Castillo R, Cisteró-Bahima A, et al.(2004) Tolerance of a cluster schedule with a house dust mite extract quantified in mass units: multicentre study. J Investig Allergol Clin Immunol 4: 193-197. (Pubitemid 39390275)
21. Garde J, Ferrer A, Jover V, Pagan JA, Andreu C, et al.(2005) Tolerance of a Salsola kali extract standardized in biological units administered by subcutaneous route. Multicenter study. Allergol Immunopathol (Madr) 33: 100-104. (Pubitemid 40571471)
22. Martínez-Cañavate A, Eseverri JL, Ródenas R, Tabar AI, Gardee J, et al.(2005) Evaluation of paediatric tolerance to an extract of Alternaria alternata under two treatment regimes. A multicentre study. Allergol Immunopathol (Madr) 33: 138-141. (Pubitemid 40896349)
23. Casanovas M, Martín R, Jiménez C, Caballero R, Fernández-Caldas E (2006) Safety of an Ultra-Rush Immunotherapy Build-Up Schedule with Therapeutic Vaccines Containing Depigmented and Polymerized Allergen Extracts. Int Arch Allergy Immunol 139: 153-158. (Pubitemid 43177328)
24. Justicia JL, Barasona MJ, Serrano P, Moreno C, Guerra F (2007) Predicting Patients at High-Risk of Systemic Reactions to Cluster Allergen Immunotherapy: A Pilot Prospective Observational Study. J Investig Allergol Clin Immunol 17: 386-392. (Pubitemid 350232563)
25. Pfaar O, Mösges R, Hörmann K, Klimek L (2009) Cluster immunotherapy of persistent allergic rhinoconjunctivitis. Safety aspects of induction therapy with mite depot allergen preparations. HNO 57: 1099-1105.
26. Pfaar O, Klimek L, Fischer I, Sieber J, Amoroso S, et al.(2009) Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens. Int Arch Allergy Immunol 150: 102-108.
27. Zenner HP, Baumgarten C, Rasp G, Fuchs T, Kunkel G, et al.(1997) Short-term immunotherapy: A prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. J Allergy Clin Immunol 100: 23-29.
28. Polosa R, Li Gotti F, Mangano G, Paolino G, Mastruzzo C, et al. (2004) Effect of immunotherapy on asthma progression,BHR and sputum eosinophils in allergic rhinitis. Allergy 59: 1224-1228. (Pubitemid 39389479)
29. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR (2001) Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 107: 87-93. (Pubitemid 32105250)
30. Crimi N, Li Gotti F, Mangano G, Paolino G, Mastruzzo C, et al. (2004) A randomized, controlled study of specific immunotherapy in monosensitized subjects with seasonal rhinitis: effect on bronchial hyperresponsiveness, sputum inflammatory markers and development of asthma symptoms. Ann Ital Med Int 19: 98-108.
31. Nanda A, O'connor M, Anand M, Dreskin SC, Zhang L, et al.(2004) Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 114: 1339-1344.
32. Tabar AI, Echechipía S, García BE, Olaguibel JM, Lizaso MT, et al.(2005) Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol 116: 109-118. (Pubitemid 40909756)
33. Colás C, Monzón S, Venturini M, Lezaun A (2006) Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. J Allergy Clin Immunol 117: 810-816. (Pubitemid 44313815)
34. Subiza J, Feliú A, Subiza JL, Uhlig J, Fernández-Caldas E (2008) Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of treatment. Clin Exp Allergy 38: 987-994. (Pubitemid 351725861)
35. Zhang L, Wang C, Han D, Wang X, Zhao Y, et al. (2009) Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis. Int Arch Allergy Immunol 148: 161-169.
36. Lou W, Wang C, Wang Y, Han D, Zhang L (2012) Responses of CD4(+) CD25(+) Foxp3(+) and IL-10-secreting type I T regulatory cells to cluster-specific immunotherapy for allergic rhinitis in children. Pediatr Allergy Immunol 23: 140-149.
37. Malling HJ, Weeke B(1993) EAACI position paper: immunotherapy. Allergy 48: 7-35.
38. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN (1999) Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 104: 364-369. (Pubitemid 29420434)
39. Freeman J (1930) Rush inoculation with special reference to hay fever treatment. Lancet 215: 744-747.